 Neurotrope, Inc. Nasdaq: NTRP today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimers disease AD. The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health NIH under a 2.7 million grant to Neurotrope. After reviewing the data from the previous trial with Key Opinion Leaders and the NIH, we designed a study to evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda memantine in patients with AD. The Company has engaged Worldwide Clinical Trials to initiate site recruitment and activation. 